Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone.
Therapeutic radiation is commonly used in the treatment of squamous cell carcinoma of the oral cavity and pharynx. Despite the proven efficacy of this form of anticancer therapy, high-dose radiation treatment is invariably associated with numerous unwanted side effects. This is particularly true for bone, in which radiation treatment often leads to osteoradionecrosis. The aim of this study was to investigate if treatment with arsenic trioxide (As(2)O(3)) could enhance the antitumor effect of radiotherapy whereas minimizing the destructive effects of radiation on bone. As(2)O(3) treatment induced a dose-dependent (1-20 mumol/L) inhibition of endothelial and tumor cell (OSCC-3 and UM-SCC-74A) survival and significantly enhanced radiation-induced endothelial cell and tumor cell death. In contrast, As(2)O(3) treatment (0.5-7.5 mumol/L) induced the proliferation of osteoblasts and also protected osteoblasts against radiation-induced cell death. Furthermore, As(2)O(3) treatment was able to significantly enhance radiation-induced inhibition of endothelial cell tube formation and tumor cell colony formation. To test the effectiveness of As(2)O(3) and radiation treatment in vivo, we used a severe combined immunodeficiency mouse model that has a bone ossicle and tumor growing side by side subcutaneously. Animals treated with As(2)O(3) and radiation showed a significant inhibition of tumor growth, tumor angiogenesis, and tumor metastasis to the lungs as compared with As(2)O(3) treatment or radiation treatment alone. In contrast, As(2)O(3) treatment protected bone ossicles from radiation-induced bone loss. These results suggest a novel strategy to enhance the therapeutic efficacy of radiation treatment while protecting bone from the adverse effects of therapeutic radiation.
Kumar
Pawan
P
Department of Biologic and Materials Sciences, University of Michigan School of Dentistry, 1011 North University Avenue, Room no. 5205, Ann Arbor, MI 48109, USA. pksuri@umich.edu
Gao
Qinghong
Q
Ning
Yu
Y
Wang
Zhuo
Z
Krebsbach
Paul H
PH
Polverini
Peter J
PJ
D000818:Animals; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology / Q000627:therapeutic use*; D001862:Bone Resorption / Q000473:pathology; D001842:Bone and Bones / Q000528:radiation effects*; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy*; D016923:Cell Death / Q000187:drug effects / Q000528:radiation effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D009062:Mouth Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy*; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D010087:Oxides / Q000494:pharmacology / Q000627:therapeutic use*; D011839:Radiation, Ionizing; D016896:Treatment Outcome; D014410:Tumor Stem Cell Assay; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology
D001152:Arsenicals; D010087:Oxides; D042461:Vascular Endothelial Growth Factor A; D000077237:Arsenic Trioxide